ge biopharma acquisit lead growth futur
maintain buy rate upgrad tp
estim tp base forward
price-to-earnings multipl adjust ep
expect price/sal give upsid
potenti
estim top line revenu growth
due acquisit
expect provid addit sale earn growth
opportun dhr life scienc segment
estim base follow factor strong
growth revenu increas stock price strong growth
life scienc diagnost environment appli
sale grew grew
core revenu growth
 expens increas increas
increas due new
suffer risk aris higher
cost expens cost sale rose y/i
sg expens grew
total revenu life scienc segment increas
increas
sale led strong sale growth china
western europ
compani name corp tickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric sep week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corp septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu diagnost segment increas
increas
sale segment clinic lab
busi increas y/i basi due increas
demand high-growth market led china
total revenu dental segment decreas
decreas
revenu growth specialti
product technolog busi consist
implant system orthodont product led high
growth market primarili china
total sale environment appli solut segment
increas increas
revenu growth
businesss chemic treatment solut product line
driven higher demand
oil ga primari metal food beverag
consum industri end market
expect ep rang
non-gaap adjust ep expect
rang ep
expect rang
non-gaap ep expect rang
current price-to-earnings multipl
due increas stock
price averag price-to-earnings
expect forward price-to-earnings multipl
dhr ytd stock perform compar
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend ex-dividend last split factor new per last split date jul inform danah corp septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
total gross research sale gener oper interest incom interest expens interest incom tax incom minor interest net incom outstand dilut ep total dilut ep normalis estim annual actual annual actual quarterli incom statement item danah corp septemb
 equival market secur account receiv total prepaid expens current asset -- -- -- -- -total current asset improv -- build improv -- machineri furnitur -- total fix asset intang excess non-curr deffer incom tax -- -- -- -- -other non-curr asset total non-curr asset total asset equiti liabil account payabl accru expens defer revenu -- current liabil -- -- -- -- -total current liabil long-term debt defer incom tax -- -- -- -- -other non-curr liabil minor interest liabil total non-curr liabil -- -- -total liabil -- -- -prefer stock equiti -- -common stock equiti addit paid-in-capit retain earn treasuri stock -- -- -- -- -total capit total equiti total liabil stock equiti balanc sheet itemsactu annual actual quarterli corp septemb
oper cash flow increas compar
due aggreg trade account receiv inventori trade account payabl use
oper cash flow first six-month compar oper cash flow
provid compar period
net cash use invest activ compar
decreas due capit expenditur made primarili increas capac replac
equip support new product develop improv inform technolog system
manufactur instrument use otl arrang certain compani busi
enter custom
net cash provid financ activ compar
oper gain increas decreas receiv decreas increas payabl decreas increas current liabil decreas increas work -- -- -other non- item -- -- -net continu oper net total oper activ invest activ sale properti plant equip purchas properti plant equip acquisit -net invest activ financ activ issuanc debt -- -- -issuanc capit stock payment dividend financ charg net discontinu financ activ -- -- -- net cash financ effect exchang rate chang net chang equival begin period end period actual annual actual quarterli statement corp septemb
strong start core revenu growth
total revenu increas compar
sale growth core basi acquisit
increas revenu impact foreign currenc translat
decreas revenu
cog increas compar
gross profit increas compar
gross profit margin
compar
sg expens increas compar
sg expens sale
compar
 expens increas compar
 expens sale
compar decreas expens sale
decreas due higher sale volum quarter
oper profit increas compar
oper profit margin decreas
compar
incom net compar
interest expens compar
interest incom compar
effect tax rate compar
effect tax rate differ feder statutori
rate princip due impact earn outsid unit state
gener tax rate lower feder rate
compar
increas
compar
compar
compar
effect tax rate includ net discret tax benefit
per dilut share releas reserv uncertain tax
posit due expir statut limit benefit chang
tax law certain foreign jurisdict excess tax benefit stock-
base compens decreas partial off-set charg audit
settlement discret tax benefit decreas report tax rate
net earn increas compar
ep compar
non-gaap ep compar
total revenu increas compar
sale grew core basi acquisit
increas revenu impact foreign currenc translat
decreas revenu
cog increas compar
increas primarili due impact higher y/i sale
volum includ sale recent acquir busi partli off-set
increment y/i cost save associ restructur continu
product improv action taken
gross profit increas compar
gross profit margin compar
gross margin decreas due impact product
mix higher freight tariff cost
decreas partial off-set impact higher y/i sale volum
includ sale recent acquir busi increas leverag certain
manufactur cost increment y/i cost save associ
restructur activ continu product improv action taken
sg expens increas compar
sg expens sale
compar decreas sg sale
driven benefit increas leverag compani gener
administr cost base result higher sale volum
decreas partial off-set invest sale market growth
initi provis legal matter also partial off-set y/i
decreas sg expens percentag sale
 expens increas compar
 expens sale flat
 expens sale remain flat y/i
increas compani new product develop initi roughli
correspond increas sale
oper profit decreas oper profit
margin decreas compar
decreas due increment dilut effect acquir busi
transact cost incur relat ge biopharma acquisit
cost estim liabil relat legal conting cost
incur relat envista ipo includ separ relat
activ cost relat establish new separ compani
infrastructur primarili relat increment salari benefit rent
expens gain resolut acquisition-rel matter
decreas partial off-set higher core sale volum
increment y/i cost save associ continu product
improv initi taken net increment y/i cost associ
variou new product develop sale servic market growth
invest impact foreign currenc exchang rate
acquisit relat transact cost deem signific fair valu
adjust inventori incur
compar
decreas
incom net compar
interest expens compar
interest incom compar
effect tax rate compar
effect tax rate differ feder statutori rate
princip due impact net discret charg
per dilut share relat primarili chang estim associ
prior period uncertain tax posit audit settlement net releas
reserv uncertain tax posit due expir statut
limit releas valuat allow associ certain foreign tax
credit tax benefit stock-bas compens
discret incom tax charg increas report tax rate
increas tax rate partial off-set benefit impact earn
outsid unit state gener tax rate lower
net earn decreas compar
ep compar
non-gaap ep compar
net earn declin
compar
danah report segment includ life scienc diagnost dental
revenu increas
compar
life scienc segment offer broad rang research tool scientist
use studi basic build block life includ gene protein
metabolit cell order understand caus diseas identifi new
therapi test new drug vaccin
segment also lead provid filtrat separ purif
technolog biopharmaceut food beverag medic aerospac
microelectron gener industri sector
sale
busi broad rang
grew y/i basi
led strong
sale growth high
particularli china
total revenu increas compar
total revenu increas
compar price increas segment contribut
sale growth y/i basi
reflect compon core revenu growth
sale busi broad rang mass spectromet grew y/i
basi led strong sale growth high
sale growth market particularli china western europ
growth driven demand pharmaceut
end-market servic offer partial off-set lower core sale
clinic end-market north america due difficult prior year comparison
sale microscopi product grew across
major product line led north america china
demand busi flow cytometri particl count product line
increas across major geographi partial driven new product
sale filtrat separ purif technolog increas
across major geographi led growth biopharmaceut
aerospac fluid technolog process industri end-market
partial off-set soft microelectron end-market
idt revenu grew
y/i basi growth
across major product
line major
driven north america
sale growth acquisit primarili due acquisit
april provid addit sale earn growth opportun
segment expand segment product line divers includ new
product servic offer area genom consum
idt revenu grew y/i basi growth across
major product line major geographi primarili driven north
ge biopharma acquisit expect complet fourth quarter
subject customari condit includ receipt applic regulatori
approv upon close compani expect includ ge biopharma
busi within life scienc segment
ge biopharma acquisit expect provid addit sale
earn growth opportun compani life scienc segment
expand busi geograph product line divers includ new
product servic offer area process chromatographi
instrument consum complement compani current
oper profit increas increas
increas due higher core sale volum
increment y/i cost save net increment y/i cost associ
variou new product develop sale market growth invest
impact foreign currenc exchang rate acquisition-rel
transact cost deem signific fair valu adjust inventori
softwar servic hospit physician offic refer laboratori
critic care set use diagnos make treatment decis
total revenu increas compar
total revenu increas
compar
price increas segment contribut sale growth y/i basi
reflect compon core revenu growth
price segment significantli impact sale growth y/i
sale segment clinic lab busi increas y/i basi
due continu demand high-growth
market led china
immunoassay autom product line drove core sale growth
core sale increas molecular diagnost
busi driven demand north america high-growth market
sale acut care diagnost busi increas y/i
demand blood ga immunoassay product line
increas sale china western europ north america
sale patholog diagnost busi grew y/i
demand core histolog advanc stain product
line increas core sale north america china western europ
oper profit increas compar
oper profit decreas
compar
revenu increas
compar
sale acut
increas y/i
demand
blood ga
line increas sale
north america
decreas
compar
increment y/i cost associ variou new product develop sale
servic market growth invest unfavor product mix
impact foreign currenc exchang rate tariff net higher
core sale volum increment y/i cost save associ
restructur action continu product improv initi taken
total revenu dental segment decreas
compar total revenu decreas
compar dental
segment provid product use diagnos treat prevent
diseas ailment teeth gum support bone well
improv aesthet human smile
lead brand name innov technolog signific market
posit compani lead world-wide provid broad rang
dental consum equip servic dedic drive
technolog innov help dental profession improv clinic
outcom enhanc product
specialti product technolog busi develop manufactur
market dental implant system dental prosthet associ treatment
softwar technolog well orthodont bracket system align
equip consum busi develop manufactur
market dental equip suppli use dental offic includ digit
imag system softwar visualization/magnif system
handpiec associ consum treatment unit dental
practic equip endodont system relat consum restor
materi instrument rotari bur impress materi bond agent
cement infect prevent product
price segment neg impact sale growth y/i basi
reflect compon core revenu
sale equip consum busi declin
flat demand high growth market off-set
lower sale tradit consum develop market
sale growth driven demand
orthodont product due partial recent product launch well
demand premium implant system equip
revenu growth specialti product technolog busi
consist implant system orthodont product led high
growth market primarili china
north america also contribut core revenu growth juli
compani announc intent spin dental busi
name envista separ publicli trade compani
februari connect announc ge
biopharma acquisit compani also announc modif plan
respect envista specif intend conduct initi
public offer envista share subject satisfact certain
condit includ obtain final approv danah board
director favor rule intern revenu servic
subsequ anticip envista ipo compani current intend
distribut sharehold portion remain equiti interest
envista may includ spin envista share effect dividend
sharehold split envista share exchang
share secur combin thereof one transact
seri transact
sale growth
driven demand
partial recent
product launch well
demand
system equip
revenu growth
specialti product
technolog
busi consist
implant system
led high growth
decreas
compar
decreas
compar
compani current intend effect distribut compani
oblig pursu consumm disposit
ownership envista includ distribut specifi date
pursu distribut may subject variou condit includ
receipt necessari regulatori approv exist
satisfactori market condit receipt opinion counsel
effect separ envista connect envista ipo
togeth distribut tax-fre compani
compani sharehold feder incom tax purpos
condit distribut may satisfi compani may
decid consumm distribut even condit satisfi
compani may decid waiv one condit
consumm final term transact
oper profit decreas compar
oper profit decreas
compar
decreas due lower overal price increment y/i cost associ
sale market growth invest impact foreign
currenc exchang rate net higher core sale volum
lower spend product initi cost save associ
product initi taken
compani environment appli solut segment offer product
servic help protect import resourc keep global food
compani water qualiti busi provid instrument servic
disinfect system help analyz treat manag qualiti ultra-pur
potabl industri wast ground sourc ocean water residenti
commerci municip industri natur resourc applic
servic consum variou color appear manag
packag design qualiti manag packag convert print
mark code traceabl applic consum pharmaceut
total revenu increas compar
total revenu increas compar
price increas segment contribut sale growth y/i basi
reflect compon core
sale segment water qualiti busi increas mid singl
digit rate compar compar period
y/i core sale analyt instrument product line grew
driven increas demand north america western europ
partial off-set lower core sale china result difficult prior year
revenu growth businesss chemic treatment solut product line
driven higher demand oil ga primari
metal food beverag consum industri end market
geograph y/i core revenu growth chemic treatment solut
driven increas across major end market
led complet sever municip project
revenu growth
solut driven
increas demand
sale
busi increas
compar
compar period
geograph y/i core sale growth ultraviolet water disinfect product
driven north america western europ china
sale segment product identif busi increas low-
singl digit rate compar compar
period
increas demand mark code equip relat consum
drove core sale growth western europ north america high growth
packag color solut product servic core sale increas
geograph y/i core revenu growth
packag color solut product servic driven north
america western europ
oper profit increas compar
oper profit increas
compar
increas due higher core sale volum increment y/i cost
save associ restructur action continu product
improv initi taken impact foreign currenc
exchang rate net increment y/i cost associ sale
servic market growth invest
increas partial affect increment net dilut effect
acquir busi
sale growth
disinfect product
driven north america
western europ
increas
compar
oper
profit increas
compar
expect ep
rang
non-gaap
adjust ep expect
rang
guidanc conclus
full year expect ep rang
expect non-gaap ep rang
expect ep adjust ep
rang
total revenu increas increas
sale grew core basi
total revenu life scienc segment increas
increas growth driven
price increas segment contribut increas y/i result
total revenu diagnost segment increas
increas growth due increas
core sale immunoassay autom product line clinic lab
total revenu dental segment declin
decreas decreas due
neg impact price segment affect sale growth
y/i
total revenu environment appli solut increas
increas growth
due price increas segment affect sale growth
y/i
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm basi increas compar
oper margin ttm basi increas compar
net margin ttm basi decreas compar
y/i revenu growth ttm basi decreas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp septemb
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale danah corp septemb
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth mrqfinanci mrqreturn mrqreturn asset danah corp septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corp septemb
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc net issuanc prefer stock- net issuanc net chang capit free corp septemb
current price-to-earnings multipl due increas stock
price averag price-to-earnings expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc price row associ fmr wellington manag compani massachusett servic morgan america northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard specialized-dividend growth price row capit apprciat fund spdr etf mf seri trust i-mf valu vanguard institut fund-institut fidel contrafund price row chip growth fund fidel corp septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
roa roi roe ttm
basi stood
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corp septemb
consensu view analyst trend stock
rate expect
compar
 growth
rate
dhr forward price-to-earnings
higher
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr danah corp septemb
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show upward trend quarter surg juli current
trade
stock gave return period
stock price volatil show upward trend surg juli
stock gave return past one year rang stock
stock price shown upward trend given total return
rang stock
danah deliv strong perform quarter growth revenu
increas adjust ep recommend buy rate tp
base continu strong perform quarter
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
